Zafgen Closes Series E Financing for Obesity Candidate
By Catherine Shaffer
Wednesday, December 4, 2013
Zafgen Inc. will funnel its latest $45 million financing into development of its rapidly advancing obesity candidate, beloranib. The financing round included a number of new investors as well as existing investor Alta Partners, which led Zafgen’s Series D round in 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.